Active Biotech - Rebound alter Schwede?!
Seite 1 von 3
neuester Beitrag: 11.01.21 06:21
|eröffnet am:||31.07.15 17:47 von:||Balu4u||Anzahl Beiträge:||56|
|neuester Beitrag:||11.01.21 06:21 von:||Carolleta||Leser gesamt:||14510|
|bewertet mit 3 Sternen
Balu4u : Active Biotech - Rebound alter Schwede?!
RichyBerlin : Active Biotech HV 19.05.2020
The shareholders of Active Biotech AB (publ) are invited to the Annual General Meeting of shareholders to be held on Tuesday, May 19, 2020, at 5 p.m. in the Company?s offices, Scheelevägen 22 in Lund, Sweden.
INFORMATION RELATING TO THE CORONA VIRUS
As a result of the Corona virus, Active Biotech kindly asks the shareholders not to participate in this years? Annual General Meeting in person..."
RichyBerlin : Active Biotech - Präsentation
"Financial impact of new direction
Our new direction aims at advancing the projects in well-defined focus areas by
leveraging existing results in combination with smaller proof-of-concept studies to
enable early and cost-effective value crystallization to Active Biotech through
? Available cash is scheduled to finance activities in the new direction through 2021
? New project programs planned to reach significant value increase during this time
? Active Biotech is evaluating corporate development opportunities to broaden the
shareholder base and to strengthen the project portfolio"
RichyBerlin : Active Biotech - Außerord.HV am 30.11.2020
"...New share issue (item 6)
The Board of Directors proposes that the Meeting resolves to increase the company?s share capital through issue of new shares.
The shareholders of the company shall be entitled to subscribe for the new shares with pre-emptive rights. Subscription can also be made without any pre-emptive rights, as set forth in the complete issue resolution.
The record date for the right to participate in the rights issue shall be 4 January 2021. Subscription for new shares shall be made during the period 7 ? 21 January 2021.
The board of directors shall, not later than 25 November 2020 present its proposal on (i) the highest amount that the company?s share capital may be increased by, (ii) the highest number of shares that may be issued and (iii) the subscription price for each new share..."
RichyBerlin : ActiveBiotech - Heute 14Uhr
ACTIVE BIOTECH UPDATES ITS CLINICAL STRATEGY AND PROJECTED MILESTONES
November 24, 2020 08:00 (CET)REGULATORY
Active Biotech AB (publ) (ticker: ACTI) today announced updates of its fully owned projects tasquinimod and laquinimod, as well the project naptumomab, developed in partnership with NeoTX Therapeutics. Investors, analysts and media are invited to today?s virtual Capital Markets Day where the current status and future developments of the company?s clinical portfolio and its future strategy will be highlighted.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, helen@firstname.lastname@example.org
Hans Kolam, CFO, +46 46 19 20 44, email@example.com
RichyBerlin : ACTI / Dem Markt gefällts
RichyBerlin : ACTI jetzt schon +49%
Projected future milestones:
? Safety readout and start of MTD (maximum tolerated dose) cohort of phase 1b study
? Safety readout and MTD expansion for single agent tasquinimod
? Start of combination study with tasquinimod and IRd
? Start of oral Proof-of-principle phase 2 study
? Start of phase 1 topical eye formulation study
? Start of phase 2 study in ?cold tumors? in combination with durvalumab
? Start of phase 2 study in Non-Small Cell Lung Cancer in combination with docetaxel
? Safety readout of combination study with tasquinimod and IRd Naptumomab
? Readout of MTD cohort of the phase 1b study regarding safety and preliminary effect
? Preliminary response readout of single agent tasquinimod
? Start of expansion cohort of combination study
? Safety readout of phase 1 topical eye formulation study
? Start of phase 2b study of single agent tasquinimod
? Proof-of-principle readout of oral phase 2 study
? Readout of phase 2 studies ?cold tumors? in combination with durvalumab
? Readout phase 2 study in Non-Small Cell Lung Cancer in combination with docetaxel
?I am very pleased with the progress we have achieved across our development projects since our new research focus was announced earlier this year, and we have a busy schedule ahead of us in the next coming years. The proposed rights issue of SEK 75 million which we announced recently will be used for advancing our prioritized project activities,? said Active Biotech?s CEO Helén Tuvesson."
RichyBerlin : ACTI
December 11, 2020
Active Biotech Receive Milestone Payment From Neotx
Active Biotech AB (publ) today announce a milestone payment of USD 750 000 from the partner NeoTX Therapeutics (NeoTX) under the terms of license agreement on the immunotherapy naptumomab.
Based on preclinical data and the previous clinical experience of naptumomab, a phase Ib/II study in patients with advanced solid tumors was initiated by NeoTX, in cooperation with AstraZeneca, in 2019. The study is currently ongoing, and the results from the dose escalation part of the study are expected early next year. NeoTX plans to expand the clinical program in the combination of naptumomab and durvalumab with focus on indications in so-called ?cold tumors? with poor response to checkpoint inhibition alone, as well as evalutate further combination strategies such as the combination with docetaxel.
About the agreement
In 2016, Active Biotech and NeoTX entered into a partnership for the development and commercialization of naptumomab in cancer indications. Under the terms of the agreement, Active Biotech has granted NeoTX exclusive rights to develop and commercialize naptumomab worldwide in cancer indications. The total deal value amounts to USD 71 million and is contingent upon achievement of clinical, regulatory and commercial milestones whereof Active Biotech has received so far USD 250 000. In addition, NeoTX will pay Active Biotech progressive, double-digit royalties on its net sales of naptumomab.